Preliminary Injunction Against Boston Scientific's Guidezilla(TM) Catheter Vacated by Federal Circuit
April 15 2014 - 11:50AM
Vascular Solutions, Inc. (Nasdaq:VASC) announced that a three judge
panel of the U.S. Court of Appeals for the Federal Circuit today
vacated the preliminary injunction that was previously issued by
the District Court for the District of Minnesota effective January
13, 2014 against Boston Scientific's Guidezilla guide extension
catheter. In its one paragraph opinion vacating the injunction, the
Court noted that a preliminary injunction is a "drastic and
extraordinary remedy that is not to be routinely granted" and "at
this stage of the case the record is too incomplete . . . to
warrant the grant of a preliminary injunction."
The Court's ruling on the preliminary injunction does not affect
the underlying patent litigation, which is currently scheduled to
be ready for trial on or after March 2015 in the District Court for
the District of Minnesota.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company
that focuses on developing unique clinical solutions for coronary
and peripheral vascular procedures. The company's product line
consists of more than 80 products in three categories: catheter
products, hemostat products and vein products. Vascular
Solutions delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein
specialists through its direct U.S. sales force and international
independent distributor network.
The information in this press release contains forward-looking
statements that involve risks and uncertainties. Our actual results
could differ materially from those anticipated in these
forward-looking statements. Important factors that may cause such
differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2013 and other recent filings
with the Securities and Exchange Commission. The risks and
uncertainties include, without limitation, risks associated with
the need for adoption of our new products, lack of sustained
profitability, exposure to intellectual property claims,
significant variability in quarterly results, exposure to possible
product liability claims, the development of new products by
others, doing business in international markets, the availability
of third party reimbursement, and actions by the FDA. The District
Court grant of preliminary injunction may be stayed or overturned
on appeal, and the granting of a preliminary injunction is not a
determination of the ultimate merits of the litigation, which will
be determined by the presentation of evidence at trial or in future
dispositive motions.
For further information, connect to www.vasc.com.
CONTACT: Vascular Solutions, Inc.
Howard Root, CEO
HRoot@vasc.com
(763) 656-4200
Vascular Solutions, Inc. (NASDAQ:VASC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Solutions, Inc. (NASDAQ:VASC)
Historical Stock Chart
From Apr 2023 to Apr 2024